A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

Clinical trial NCT02340208 · COMPLETED

Trial details

NCT number: NCT02340208
Sponsor: Helix BioPharma Corporation
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2012-05-01
Primary completion: 2017-08-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.